Stockscreener 앱 받기
7.09
4.11%
0.28
전일 마감가:
$6.81
열려 있는:
$6.99
하루 거래량:
339.74K
Relative Volume:
0.96
시가총액:
$275.24M
수익:
$5.74M
순이익/손실:
$-166.12M
주가수익비율:
-1.7735
EPS:
-3.9978
순현금흐름:
$-131.64M
1주 성능:
+12.36%
1개월 성능:
+20.37%
6개월 성능:
-35.31%
1년 성능:
+0.85%
1일 변동 폭
$6.7601
$7.205
1주일 범위
$6.19
$7.205
52주 변동 폭
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.09 | 275.24M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-11 | 개시 | Guggenheim | Buy |
| 2026-01-28 | 개시 | Oppenheimer | Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
모두보기
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - TipRanks
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out | NDAQ:TRDA | Press Release - Stockhouse
Behavioral Patterns of TRDA and Institutional Flows - Stock Traders Daily
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDA - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com India
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679 - Minichart
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
User - The Chronicle-Journal
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress - TipRanks
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors - Stock Titan
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):